The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition

Fertility and Sterility

Volumn 81, Issue 6, 2004, Pages 1498-1501

  Naftolin, Frederick ^a   Taylor, Hugh S ^a   Karas, Richard ^b   Brinton, Eliot ^c   Newman, Isadore ^d   Clarkson, Thomas B ^e   Mendelsohn, Michael ^b   Lobo, Rogerio A ^f   Judelson, Debra R ^g   Nachtigall, Lila E ^h   Heward, Christopher B ⁱ   Hecht, Harvey ^j,k   Jaff, Michael R ^l   Harman, S Mitchell ^l  

^a YALE UNIVERSITY   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c CARL T HAYDEN VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF AKRON   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f College of Physicians and Surgeons ^*  (United States)

^g Cardiovascular Medical Group of Southern California   (United States)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Research and Development   (United States)

^j BETH ISRAEL MEDICAL CENTER   (United States)

^k LENOX HILL HOSPITAL   (United States)

^l Kronos Longevity Research Institute   (United States)

more..

Author keywords

cardiovascular disease; estrogen; Menopause; progestin; randomized clinical trial; WHI

Indexed keywords

ESTROGEN; GESTAGEN;

AGE DISTRIBUTION; BONE STRUCTURE; CLIMACTERIUM; CLINICAL TRIAL; FEMALE; HEALTH; HEALTH CARE ORGANIZATION; HEART PROTECTION; HORMONAL THERAPY; HUMAN; MEDICAL INFORMATION; MENOPAUSAL SYNDROME; OSTEOLYSIS; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 2942612542     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2004.02.095     Document Type: Article

References (14)

1. Grodstein F., Manson J.E., Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. A prospective, observational study. Ann Intern Med. 135:2001;1-8
2. Lindsay R. Management of osteoporosis. Baillieres Clin Endocrinol Metab. 2:1988;103-124
3. Mikkola T.S., Clarkson T.B. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 53:2002;605-619
4. Haynes M.P., Li L., Russell K.S., Bender J.R. Rapid vascular cell responses to estrogen and membrane receptors. Vasc Pharmacol. 38:2002;99-108
5. Karas R.H., Clarkson T.B. Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI timing is everything. Menopausal Med. 10:2003;8-12
6. Diano S., Horvath T.L., Mor G., Register T., Adams M., Harada N., et al. Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and humans. Menopause. 6:1999;21-28
7. Stampfer M.J., Colditz G.A., Willett W.C., et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med. 325:1991;756-762
8. Langer R.D. Legend meets reality estrogen plus progestin and coronary heart disease in the Women's Health Initiative. Menopausal Med. 10:2003;5-7
9. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333
10. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 349:2003;523-534
11. Hays J., Ockene J.K., Brunner R.L., et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 348:2003;1839-1854
12. Hu F.B., Stampfer M.J., Manson J.E., et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med. 343:2000;530-537
13. Shapiro S. Effects of hormone replacement therapy on the risks of breast cancer and cardiovascular disease: the validity of the epidemiological evidence. In: Schneider HPG, Naftolin F, eds. Climacteric medicine - where do we go? Proceedings of the 4th Workshop of the International Menopause Society. London: Parthenon Publishing. In press
14. International Menopause Society Executive Committee. Guidelines for the hormone treatment of women in the menopausal transition and beyond: Position Statement by the Executive Committee of the International Menopause Society. Climacteric 2004;7:8-11